Search

A study conducted at Sun Yat-sen University in Guangzhou, China, explored the mechanism of anlotinib resistance in oral squamous cell carcinoma (OSCC) cells. The research found that SOD2 expression levels were positively correlated with anlotinib resistance in OSCC cells and PDX models. The study suggests that SOD2 could be a potential therapeutic target to enhance the anti-cancer efficacy of anlotinib in OSCC. This research was funded by the Guangdong Provincial Applied Science and Technology Research and Development Program and the National Natural Science Foundation of China. [Extracted from the article]

A 55-year-old woman with ovarian large-cell neuroendocrine carcinoma (LCNEC) experienced drug allergy to carboplatin, immune-related hepatitis from pembrolizumab and bevacizumab, and lack of efficacy with various chemotherapy treatments. Despite multiple treatment attempts, including targeted radiotherapy and trastuzumab deruxtecan, the disease continued to progress. The woman eventually participated in a clinical trial after experiencing disease relapse. [Extracted from the article]

A 57-year-old man with pancreatic neuroendocrine carcinoma (pNEC) stage IV and bone metastases experienced a drop in white blood cell count during treatment with etoposide and cisplatin. Despite receiving catequentinib for pNEC, he exhibited lack of efficacy. After multiple treatment regimens and disease progression, the man eventually passed away a month after discontinuing antitumor treatment. The case highlights the challenges and complexities of managing advanced cancer cases. [Extracted from the article]

A 65-year-old woman experienced acquired drug resistance during treatment for stage IV lung adenocarcinoma with osimertinib and catequentinib. She also showed lack of efficacy with cisplatin for the same condition, and with etoposide and carboplatin for extensive-stage small cell lung cancer. Additionally, she developed a reduction in left ventricular ejection fraction while on osimertinib and catequentinib. Despite various treatments, her condition worsened, leading to metastasis and ultimately a decision to discontinue therapy and opt for hospice care. [Extracted from the article]

The article in Reactions Weekly describes two case reports of men aged 64-66 with extensive stage small cell lung cancer who exhibited lack of efficacy during treatment with various drugs. Patient 1 initially responded well to traditional chemotherapy but later experienced worsened symptoms with catequentinib. Patient 2 also showed lack of efficacy to etoposide, cisplatin, and tislelizumab, eventually leading to his death in September 2022. The article provides detailed accounts of the treatment courses and outcomes for both patients, highlighting the challenges in managing advanced lung cancer. [Extracted from the article]

A 12-year-old girl with embryonal rhabdomyosarcoma (ERMS) in her maxillary gingiva showed lack of efficacy with vincristine, dactinomycin, and cyclophosphamide treatment. Despite developing a lung infection during treatment, she responded well to off-label treatment with catequentinib, leading to tumor reduction and successful excision. Genetic alterations were identified, and the patient was discharged in a stable condition after the second cycle of catequentinib. [Extracted from the article]

The article in "Reactions Weekly" discusses a case report of a 67-year-old woman with stage IVb EGFR-wt NSCLC and MET amplification who showed lack of efficacy while being treated with entrectinib. Despite her medical history of brain metastases, she received entrectinib for CHSY1-NTRK fusion and MET amplification but experienced disease progression and required ICU care. Subsequent treatment with savolitinib led to an improvement in performance status and partial response, followed by catequentinib which resulted in a progression-free survival of seven months with a consistent safety profile. [Extracted from the article]

A 64-year-old woman with recurrent metastatic renal pelvic sarcomatoid urothelial carcinoma experienced lack of efficacy with doxorubicin and carboplatin treatment. She also developed hand and foot skin syndrome, hypertension, and immune-related hypothyroidism during subsequent treatments with catequentinib and toripalimab. Despite adverse reactions, the woman underwent various procedures and chemotherapy cycles before achieving a clinical cure with toripalimab and anlotinib, leading to no tumor recurrence two years after treatment cessation. [Extracted from the article]

A cohort study analyzed the use of etoposide and catequentinib in treating non-small cell lung cancer (NSCLC) in 46 patients. One patient developed grade 2 haemoptysis while on this treatment regimen, leading to the withdrawal of both medications. The patient's condition improved after receiving haemostatic drugs. [Extracted from the article]

A 56-year-old man with adenoid cystic carcinoma of the external auditory canal and pulmonary metastasis exhibited lack of efficacy with multiple drug treatments, including paclitaxel, carboplatin, bevacizumab, pemetrexed, sintilimab, irinotecan, and capecitabine. Despite initial treatments, the disease progressed, leading to changes in the treatment regimen. Anlotinib therapy showed promising results with a reduction in lung metastases and symptom relief, ultimately stabilizing the man's tumor and metastatic condition after ten cycles of treatment. [Extracted from the article]

A 34-year-old man with metastatic osteosarcoma developed grade 1 rash and oral mucositis while undergoing treatment with sintilimab and catequentinib. The man had multiple metastases and was receiving sintilimab every 3 weeks along with catequentinib and radiotherapy. Despite experiencing these side effects, he showed stable disease with a 20% shrinkage in volume. [Extracted from the article]

A 26-year-old man with HER2-mutant advanced lung adenocarcinoma experienced lack of efficacy and adverse reactions to various treatments, including pemetrexed, carboplatin, erlotinib, and sunvozertinib. Despite participating in a clinical trial and trying different medications, he faced disease progression and severe side effects such as fever, headache, diarrhea, and liver dysfunction. After multiple treatment changes and complications, he eventually showed improvement with a new regimen and was discharged with oxygen therapy. [Extracted from the article]

A study conducted at Jiangsu Province Hospital of Chinese Medicine in China explored the efficacy and safety of anlotinib plus camrelizumab as a second-line therapy for advanced esophageal squamous cell carcinoma (ESCC). The study enrolled 58 patients with advanced ESCC and compared the outcomes of those treated with anlotinib plus camrelizumab versus anlotinib plus S-1. The results showed that the anlotinib plus camrelizumab group had longer progression-free survival, higher objective response rate, and higher disease control rate compared to the anlotinib plus S-1 group. The study concluded that anlotinib plus camrelizumab exhibited promising antitumor efficacy and manageable toxicity as a second-line treatment for advanced ESCC. [Extracted from the article]

Two case reports describe patients with extensive-stage small cell lung cancer who developed kidney damage or myocarditis during treatment with atezolizumab, epirubicin, cyclophosphamide, and catequentinib. Patient 1 received these drugs for 4-6 cycles followed by maintenance therapy, but later developed kidney damage and died. Patient 2 also received these drugs and developed myocarditis, leading to their death. The study provides information on the adverse effects of these medications in this specific patient population. [Extracted from the article]

A 60-year-old woman with primary cardiac synovial sarcoma metastatic underwent treatment with ifosfamide, catequentinib, and doxorubicin-liposomal. However, she experienced lack of efficacy, with disease progression and an increase in metastatic lesions in her lungs. Despite receiving platelet transfusion and second-line chemotherapy, she died unexpectedly from significant haemoptysis. This case report highlights the lack of effectiveness of the treatment regimen for this particular patient. [Extracted from the article]

In a retrospective observational study of 44 women with epithelial ovarian cancer (EOC), four women experienced adverse reactions while being treated with catequentinib. The adverse reactions included hand and foot syndrome, thrombocytopenia, pain, and leukopenia. All four women developed grade 3 adverse reactions, leading one woman to discontinue the treatment after five cycles. The study highlights the potential toxicities associated with catequentinib in EOC patients. [Extracted from the article]

A retrospective analysis of 533 cancer patients between 2013 and 2020 found that 91 patients developed multi-system toxicities during treatment with various antineoplastic drugs. The patients experienced a range of adverse drug reactions, including rash, asthenia, neurotoxicity, nausea and vomiting, alopecia, and many others. The study did not provide information on the ages or sexes of the patients, nor did it specify the dosages or routes of administration for the drugs. The duration of treatment and outcomes of the reactions were also not stated. [Extracted from the article]

A 57-year-old woman with HER2 positive breast cancer and brain metastases experienced various toxicities and lack of efficacy during her treatment. She initially received capecitabine and pyrotinib, but developed diarrhea, nausea, and vomiting. Subsequent treatment with paclitaxel, trastuzumab, pertuzumab, and capecitabine also showed lack of efficacy. The woman underwent whole brain radiation therapy and started receiving anlotinib, pyrotinib, and letrozole, which resulted in successful tumor control. [Extracted from the article]

A case report published in Reactions Weekly describes the treatment and outcomes of an adult patient with stage IIIB non-small cell lung cancer (NSCLC). The patient initially received therapy with pemetrexed and carboplatin, but experienced disease progression. They then started second-line monotherapy with nivolumab, which initially showed a positive response but later led to pneumonia and gastritis. The patient subsequently received treatment with catequentinib, paclitaxel, and cadonilimab, but experienced lack of efficacy and developed acquired drug resistance. Unfortunately, the patient passed away in April 2023. [Extracted from the article]

A 66-year-old man with adrenocortical carcinoma and lung metastases underwent off-label combination treatment with etoposide, cisplatin, sintilimab, and catequentinib. He experienced decreased appetite and grade 1 bone marrow suppression during the treatment. Additionally, he developed grade 1 hypertension and grade 1 hypothyroidism during off-label combination treatment with catequentinib and sintilimab. The patient's condition improved after receiving unspecified antihypertensives and levothyroxine-sodium. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of various antineoplastic drugs in the treatment of metaplastic breast cancer (MBC) in an adult patient. The patient underwent surgery and received adjuvant therapy, but in December 2019, imaging tests showed metastasis to the lung and left pleura, indicating a lack of response to the initial treatment. The patient subsequently received multiple treatment regimens, including different combinations of drugs, but disease progression was observed in each case. Unfortunately, the patient died from MBC in June 2023. [Extracted from the article]

A recent study conducted at the Fourth Hospital of Hebei Medical University evaluated the efficacy and safety of anlotinib, a tyrosine kinase inhibitor, in the treatment of recurrent epithelial ovarian cancer (EOC). The study included 51 patients, with 26 patients receiving anlotinib monotherapy. The median progression-free survival (PFS) was 4.0 months, and the median overall survival (OS) was not reached. Anlotinib demonstrated mild efficacy when used as monotherapy, combined with chemotherapy, or as maintenance therapy. The most common adverse effects were fatigue, hypertension, nausea and vomiting, and hand-foot syndrome. This research suggests that anlotinib may be a viable treatment option for recurrent EOC. [Extracted from the article]

A 53-year-old woman with combined large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC) experienced severe bone marrow suppression and liver function impairment during treatment with etoposide and cisplatin. She also did not respond well to the treatment, as evidenced by increased consolidation in the left upper lung and enlargement of mediastinal lymph nodes. After switching to irinotecan and catequentinib, there was no apparent progression of her LCNEC and SCLC. Unfortunately, she passed away in November 2023. [Extracted from the article]

In a retrospective study of 34 patients with extensive-stage small cell lung cancer, three cases were reported of patients developing elevated alanine aminotransferase, pneumonitis, or hypertension during treatment with camrelizumab and catequentinib. The patients received camrelizumab every 3 weeks along with catequentinib for a specific duration, but experienced these adverse reactions. The study does not provide further details about the patients' ages, sexes, treatment durations, or outcomes. [Extracted from the article]

The article focuses on evaluating the efficacy and safety of anlotinib compared to traditional chemotherapy in treating EGFR-positive advanced lung adenocarcinoma. Topics include the improved progression-free and overall survival associated with anlotinib, the comparison of response and disease control rates between anlotinib and chemotherapy, and the safety profile of anlotinib with minimal severe adverse events.

Researchers from China Pharmaceutical University have conducted a study on the use of anlotinib, a drug with antiangiogenic effects, in combination with other antitumour drugs. Through their research, they discovered that anlotinib regulates the expression of components of the extracellular matrix (ECM), leading to a reduction in ECM stiffness. This, in turn, increases the distribution and retention of antitumour drugs in tumours. The study also found that anlotinib effectively suppresses the RhoA/ROCK signalling pathway. These findings contribute to the development of combination therapies aimed at improving tumour targeting in cancer treatment. [Extracted from the article]

The article highlights a recent study from Sun Yat-sen University Cancer Center that explores the efficacy of combining gefitinib and anlotinib for treating untreated, EGFR-mutated, advanced non-small cell lung cancer (NSCLC). Topics discussed include improved progression-free survival with the combination therapy, the benefits for patients with brain metastasis or high tumor mutation load, and the manageable safety profile compared to placebo.

A retrospective study reported two cases of grade 5 nasopharyngeal, nasal, and neck bleeding in patients with head and neck cancer who were treated with catequentinib (anlotinib). The patients, whose ages and genders were not disclosed, experienced severe bleeding after starting oral catequentinib therapy. Unfortunately, both patients ultimately died as a result of the excessive bleeding, leading to the discontinuation of catequentinib treatment. [Extracted from the article]

A 52-year-old man with gallbladder neuroendocrine carcinoma showed lack of efficacy to multiple chemotherapy treatments, including etoposide, cisplatin, irinotecan, catequentinib, and cemiplimab. Despite receiving various combinations of these drugs, imaging scans revealed tumor progression and lack of response to treatment. The patient continued to receive catequentinib after the unsuccessful chemotherapy regimens. [Extracted from the article]

The article discusses a study from Peking University Cancer Hospital and Institute revealing that the combination of eribulin and anlotinib shows synergistic effects against retroperitoneal liposarcoma (RLPS) by inducing endoplasmic reticulum stress. Topics discussed include the effectiveness of this drug combination in reducing RLPS cell proliferation, the impact on tumor microenvironment.

The article focuses on a Phase 2 clinical trial evaluating the combination of chidamide, a PD-1 inhibitor, and anlotinib for treating HER2-low, unresectable, and/or metastatic breast cancer. Topics include the trial's aim to determine the treatment's efficacy and safety, the specific eligibility criteria for participants, and the planned evaluation of key outcomes such as progression-free survival and overall survival.

A 65-year-old man with tonsillar carcinoma underwent various chemotherapy treatments, including etoposide, cisplatin, irinotecan, paclitaxel, catequentinib, sindilizumab, and vinorelbine. However, these treatments were ineffective. He then received surufatinib and gemcitabine, but developed grade 2 hypertension as a side effect of surufatinib. The man's blood pressure improved with antihypertensive medication, and he achieved temporary remission of the disease. [Extracted from the article]

A 45-year-old woman with squamous cell carcinoma of the cervix experienced various toxicities during her treatment with multiple drugs. She developed haematuria, capillary hyperplasia, vaginal bleeding, myelosuppression, and a vaginal bladder fistula. She also exhibited lack of efficacy with some of the drugs. The woman underwent different treatment regimens, including chemotherapy, radiotherapy, and immunotherapy, but experienced adverse reactions and recurrence of her cancer. She was eventually switched to third-line therapy and received off-label treatment with catequentinib, which resulted in a vaginal bladder fistula and allergic reaction. Her treatment was then switched again to penpulimab. [Extracted from the article]

In a real-world study of 16 patients with extensive stage small cell lung cancer, an elderly patient developed anaemia, leukocytopenia, and lymphocytopenia during treatment with cisplatin, etoposide, and catequentinib. The patient received cisplatin and etoposide on days 1-3 of each cycle, along with oral catequentinib on days 1-14 of each cycle. Despite the development of these treatment-related side effects, the patient's disease remained stable. The exact age and sex of the patient were not stated in the report. [Extracted from the article]

A 65-year-old man with extensive-stage disease small cell lung cancer experienced slight nausea and poor appetite during treatment with etoposide and cisplatin. He also exhibited lack of efficacy during treatment with paclitaxel. The man had a medical history of type-2 diabetes, smoking, and alcohol consumption. He received immunotherapy and first-line chemotherapy, followed by thoracic intensity-modulated radiotherapy and second-line chemotherapy with minimal response. Recurrence was observed, and the patient received third and fourth-line chemotherapy with minimal response. He is currently alive and continuing on anlotinib therapy. [Extracted from the article]

A 78-year-old man with non-small cell lung cancer (NSCLC) experienced lack of efficacy with catequentinib treatment and subsequently developed immune-related myocarditis while receiving sintilimab. He also experienced a rebound effect in the form of Type 2 respiratory failure and respiratory acidosis after a dose reduction of methylprednisolone. The patient underwent thoracoscopic radical surgery for lung cancer and completed four cycles of postoperative palliative care before starting catequentinib. Despite receiving catequentinib, imaging revealed metastasis, indicating lack of efficacy. The patient was then treated with sintilimab, but developed immune-related myocarditis. Treatment with methylprednisolone led to a rebound effect and the patient was eventually stabilized and discharged. [Extracted from the article]

A new report from Nanjing University discusses the safety and efficiency of anlotinib, a multi-target TKI, in patients with recurrent grade 4 glioma. The study analyzed the clinical data of 17 patients who received anlotinib treatment and found that the median progression-free survival was 7 months and the median overall survival after recurrence was 10 months. The study also identified the existence of target genes as a variable affecting survival after recurrence. The researchers concluded that anlotinib can be considered as a supplement to the standard treatment for recurrent grade 4 glioma, especially for patients with anlotinib target genes. [Extracted from the article]

Researchers at Shanghai Jiao Tong University have conducted a study to investigate the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for the efficacy of anlotinib, a targeted therapy for advanced non-small cell lung cancer (NSCLC). The study enrolled 20 advanced NSCLC patients and identified seven differentially expressed miRNAs. Among these, miR-941 was significantly upregulated in patients with progressive disease, while the others were downregulated. The researchers concluded that sEV miRNAs have the potential to predict the benefit of anlotinib. [Extracted from the article]

A recent study conducted by researchers from Huazhong University of Science and Technology in Wuhan, China, examined the efficacy and safety of combining toripalimab and anlotinib in the treatment of Chinese patients with metastatic melanoma. The study included 47 patients with different subtypes of melanoma, and the results showed an objective response rate of 23.9% and a disease control rate of 80.4%. The median progression-free survival was 5.7 months, and the median overall survival was 14.4 months. The treatment was generally well-tolerated, with treatment-related adverse events occurring in 76.6% of patients. The researchers concluded that toripalimab combined with anlotinib showed promising efficacy and safety profiles in the treatment of metastatic melanoma. Further biomarker analysis is ongoing. [Extracted from the article]

A new report discusses research findings on mitotic inhibitors in the treatment of advanced non-small cell lung cancer (NSCLC) that has progressed after immune-checkpoint inhibitors (ICIs). The study evaluated the outcomes of anlotinib plus docetaxel versus docetaxel alone in patients with advanced NSCLC. The results showed that anlotinib plus docetaxel demonstrated improved progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) compared to docetaxel alone. However, there was no significant difference in overall survival (OS) between the two treatment arms. The study suggests that anlotinib plus docetaxel may be an effective and safe option for patients with advanced NSCLC progressing after ICIs. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Nanjing Medical University in China has found that maintenance therapy with anlotinib after platinum-based chemotherapy can significantly improve the prognosis of patients with advanced non-small cell lung cancer (NSCLC). Anlotinib was shown to be effective, tolerable, and convenient as a third-line treatment for NSCLC. The study analyzed data from two clinical trials and found that the median progression-free survival since the start of maintenance therapy was 5.95 months, with a median overall survival of 18.60 months. Anlotinib may offer a new option for maintenance treatment in patients with locally advanced or metastatic NSCLC after standard first-line platinum-based chemotherapy. [Extracted from the article]

A 41-year-old woman with extensive-stage small-cell lung cancer (ES-SCLC) experienced lack of efficacy, intolerance, and myelosuppression during treatment with various drugs. She initially received chemotherapy with irinotecan, docetaxel, gemcitabine, and sintilimab, but progressive disease was noted. She then underwent treatment with catequentinib and atezolizumab, which resulted in improvement. However, when she received chemotherapy with gemcitabine and sintilimab, progressive disease was again observed. Ultimately, she experienced improvement with a combination of bevacizumab, temozolomide, lobaplatin, serplulimab, etoposide, and cisplatin. [Extracted from the article]

A case report published in Reactions Weekly describes a patient with desmoid fibromatosis who did not respond to treatment with catequentinib. The patient, whose age and sex were not provided, received oral catequentinib at a dose of 12mg daily. However, the patient experienced disease progression, indicating a lack of efficacy for catequentinib in treating desmoid fibromatosis. This retrospective study involved 66 patients and was conducted between June 2019 and November 2023. [Extracted from the article]

This article discusses two case reports of men in their 50s who experienced various toxicities while undergoing treatment for metastatic lung adenocarcinoma. The first patient underwent multiple treatments, including chemotherapy, targeted therapy, and immunotherapy, but eventually developed hypertension and gastrointestinal side effects. The second patient also underwent multiple treatments, including targeted therapy and chemotherapy, but experienced lack of efficacy and eventually developed neurological symptoms. Both patients ultimately passed away, although the cause of death is not specified. These case reports highlight the challenges and potential side effects associated with antineoplastic treatments for lung adenocarcinoma. [Extracted from the article]

A recent study conducted in Anhui, People's Republic of China, explored the efficacy of combining anlotinib with chemotherapy in the treatment of metastatic triple negative breast cancer. The study divided 100 patients into two groups, one receiving conventional chemotherapy and the other receiving anlotinib Hydrochloride Capsules in addition to chemotherapy. After six cycles of treatment, the group receiving the combined drug treatment showed significantly increased response rates and decreased levels of certain serum factors compared to the conventional chemotherapy group. The study concluded that the combination treatment was effective, safe, and improved patient survival. [Extracted from the article]

A 15-year-old boy with alveolar soft part sarcoma (ASPS) experienced liver function impairment and tumor pseudoprogression during his treatment. He initially received cyclophosphamide and doxorubicin, but developed liver function impairment after one cycle and had to discontinue. He then received catequentinib and sintilimab, but experienced progression of lung and brain lesions. The diagnosis was tumor pseudoprogression caused by the sintilimab and catequentinib. After completing treatment, the boy achieved complete remission with a progression-free survival of 33 months. [Extracted from the article]

A retrospective study was conducted on eight patients with epithelioid sarcoma (ES) who exhibited lack of efficacy during treatment with various antineoplastic drugs. Two of the patients experienced severe adverse reactions, including pelvic soft tissue necrosis, tumor rupture, diarrhea, and dehydration, while receiving irinotecan, catequentinib, and vincristine. The patients were then switched to a different treatment regimen, which resulted in no further disease progression. However, one patient developed pelvic soft tissue necrosis and tumor rupture, requiring surgery, and another patient experienced grade 4 diarrhea and dehydration, leading to admission to the ICU and eventual death. Two other patients discontinued treatment for other reasons. [Extracted from the article]

This document provides information about a clinical trial, NCT06475599, being conducted in China to evaluate the efficacy of anlotinib hydrochloride capsules combined with TQB2450 injection in the treatment of recurrent or metastatic endometrial cancer. The trial aims to demonstrate that this combination can significantly prolong progression-free survival compared to chemotherapy in patients with specific types of endometrial cancer. The study is in the interventional phase and is randomized, controlled, open-label, and multicenter. The drugs being tested work by inhibiting tumor progression through various mechanisms. The trial is not yet recruiting participants, and the completion date is projected to be in 2029. Contact information for the primary investigator is provided. [Extracted from the article]

This document provides information about a clinical trial, NCT06475287, that aims to investigate the effectiveness and safety of a combination therapy for second-line treatment of advanced hepatocellular carcinoma (HCC). The trial involves the use of hepatic arterial infusion chemotherapy (HAIC) combined with TQB2450 and anlotinib. The study is expected to be completed by July 2025 and is taking place in China. The document includes administrative details such as the NCT number and collaborating institutions. [Extracted from the article]

A recent study conducted in Beijing, China, aimed to assess the early efficacy of anlotinib in patients with progressive radioactive iodine refractory differentiated thyroid cancer. Ten patients were enrolled in the study and their responses were assessed at 6 weeks. The study found that anlotinib led to structurally controlled disease in all patients, with a reduction in the size of target lesions. Additionally, there was a sharp reduction in serum thyroglobulin levels and a heterogeneous metabolic response. The study concluded that thyroglobulin may be an early sensitive biomarker for anlotinib, while metabolic response may play a complementary role. [Extracted from the article]